Maarten van der Doelen

Chapter 5

LD level (U/L) 33 216 [165-1045] 19 288 [175-1045] 14 208 [165-341] 0.011 LD < 250 33 20 (60.6) 19 8 (42.1) 14 12 (85.7) 0.015 ‡

1-5 radium-223 injections (N=24) 6 radium-223 injections (N=21) P n median [range] or mean ± SD or n (% † ) n median [range] or mean ± SD or n (% † ) n median [range] or mean ± SD or n (% † ) Hemoglobin (g/dL) 45 12.0 [9.3-15.4] 24 11.8 [9.3-14.9] 21 12.6 [9.9-15.4] 0.136 Hb > 10 45 40 (88.9) 24 20 (83.3) 21 20 (95.2) 0.352 ‡ Hb ≤ 10 45 5 (11.1) 24 4 (16.7) 21 1 (4.8)

Lymph node metastases 41 10 (24.4) 20 5 (25.0) 21 5 (23.8) 0.929 Visceral metastases 41 4 (10.0) 20 2 (10.0) 21 2 (9.5) 1.000 ‡

ALP level (U/L) 43 147 [60-2640] 24 180 [73-1958] 19 125 [60-2640] 0.304 ALP < 115 43 16 (37.2) 24 7 (29.2) 19 9 (47.4) 0.220

Platelet count (x 10 9 /L) 45 240 [140-466] 24 238 [140-461] 21 254 [142-466] 0.794 WBC count (x 10 9 /L) 45 7.5 [3.4-12.7] 24 21 NLR (x 10 9 /L) 35 4.20 [0.9-11.8] 19 2.90 [1.0-11.8] 16 4.59 [0.9-9.0] 0.466 NLR ≤ 3.0 35 15 (42.9) 19 10 (52.6) 16 5 (31.3) 0.203

0.912 > 20 metastases 45 28 (62.2) 24 14 58.3 21 14 66.7 Superscan* 45 8 (17.8) 24 5 20.8 21 3 14.3

PSA level (µg/L) 44 130.0 [1-6472] 23 170.0 [9-3000] 21 61.0 [1-6472] 0.142

6-20 metastases 45 9 (20.0) 24 5 20.8 21 4 19.0

LD ≥ 250 33 13 (39.4) 19 11 (57.9) 14 2 (14.3)

ALP ≥ 115 43 27 (62.8) 24 17 (70.8) 19 10 (52.6)

NLR > 3.0 35 20 (57.1) 19 9 (47.4) 16 11 (68.8)

Group

Group

Complete cohort (N=45)

Table 2. Baseline laboratory and imaging characteristics.

Extent of disease

* Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. † Percentages may not sum to 100 due to rounding. ‡ Calculated by two-sided Fisher Exact Probability Test. ALP, alkaline phosphatase; ANC, absolute neutrophil count; Hb, hemoglobin; LD, lactate dehydrogenase; NLR, neutrophil-to-lymfocyte ratio; PSA, prostate-specific antigen; WBC, white blood cell. Bold = P < 0.05.

142